300015 爱尔眼科
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入17,483,8597.25%20,982,89420,367,15716,109,94715,000,809
减:营业总成本13,272,2818.18%16,628,94215,113,23312,152,47810,986,823
    其中:营业成本8,868,84911.07%10,886,54910,021,9757,980,3897,211,887
               财务费用136,674-2.94%214,29873,6286,655106,444
               资产减值损失(665)18.66%(187,757)(383,606)(95,464)(217,209)
公允价值变动收益20,886-90.25%334,398(79,423)(356,890)(448,391)
投资收益22,644-84.79%213,22046,52343,910141,116
    其中:对联营企业和合营企业的投资收益--------(3)(59)
营业利润4,144,436-6.74%4,824,9174,947,9473,534,5003,493,998
利润总额4,039,512-7.09%4,594,2824,551,0193,335,0563,147,755
减:所得税费用672,371-1.07%858,153895,023646,059677,852
净利润3,367,141-8.21%3,736,1303,655,9962,688,9972,469,903
减:非控股权益252,40116.62%180,074297,124164,766146,559
股东净利润3,114,740-9.76%3,556,0563,358,8722,524,2312,323,344

市场价值指针
每股收益 (元) *0.337-10.04%0.3850.3640.2790.334
每股派息 (元) *0.080--0.1600.1500.1000.120
每股净资产 (元) *2.4069.97%2.2212.0212.3232.092
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容